Rapid WGS Improves Pediatric Diagnosis

Three-day whole-genome sequencing led to more personalized care for children newly diagnosed with cancer

October 15, 2026
3 min

The Pathologist

At a Glance

Category	Detail
Condition	Children evaluated for suspected or confirmed cancer; two children presenting with soft tissue lesions were diagnosed with non-malignant conditions.
Key Mechanisms	Rapid whole-genome sequencing (rWGS) analyzes germline and tumor variants and, from a single sample, provided leukemia classification, measurable residual disease markers, risk information, and pharmacogenomic data in the study.
Target Population	The study included 54 children: 35 enrolled prospectively and 19 assessed using archived samples. Participants had hematologic malignancies or solid tumors; two children presenting with soft tissue lesions were diagnosed with non-malignant conditions.
Care Setting	Single-center study comparing rWGS with routine WGS and conventional molecular tests.

Key Highlights

Average time to a clinically interpretable genomic report was 3 days with rWGS; the average across testing methods overall was 42 days.
rWGS detected 147 of 155 clinically actionable variants identified by any method; routine WGS detected 138.
The eight actionable variants missed by rWGS did not change diagnosis or management in the affected patients.
Among 35 prospectively assessed patients, clinicians reported measurable care improvements in 17, including faster diagnosis or risk stratification and access to precision treatments.
The study was small, single-center, and non-randomized, and was not designed to establish clinical impact or cost savings.

Guideline-Based Recommendations

Diagnosis

The study compared rWGS with routine WGS and conventional molecular tests, including fluorescence in situ hybridization, targeted next-generation sequencing, and RNA fusion testing.

Management

Clinicians reported faster diagnosis and risk stratification, access to precision treatments, and avoidance of unnecessary investigations or therapies among the reported care improvements.
In some cases, sequencing blood or other samples provided sufficient diagnostic information to avoid more invasive procedures.

Monitoring & Follow-up

The study reported that rWGS provided measurable residual disease markers; it did not specify a monitoring protocol.

Risks

The study was not designed to demonstrate clinical impact or cost savings.
The authors stated that larger multicenter studies are needed to establish reproducibility, cost-effectiveness, and scalability before wider implementation.

Patient & Prescribing Data

The study included 54 children with hematologic malignancies or solid tumors: 35 enrolled prospectively and 19 assessed using archived samples.

Among prospectively assessed patients, clinicians reported measurable care improvements for 17 of 35 (49%). Reported examples included access to precision treatment and avoidance of unnecessary investigations or therapies; the study did not establish comparative treatment outcomes.

Clinical Best Practices

The study found that rWGS detected 147 of 155 clinically actionable variants identified across all methods; it did not detect every such variant.
The study reported an average rWGS turnaround of 3 days, compared with 29 days for routine WGS in solid tumors and 63 days in hematologic malignancies.
The authors noted that the study was not designed to demonstrate clinical impact or cost savings and called for larger multicenter studies to establish reproducibility, cost-effectiveness, and scalability.